Targeting ORMDL2 in glioblastoma through integrated landscape of high-throughput sequencing and pharmacogenomic analysis.

Wulandari FS, Wang CY, Kumar S, Ly NP, Ngadio JL, Solomon DD, Xuan DTM, Sutandi GN, Lin HY, Lin HR, Lee YK, Yang HC, Tsai MC, Ko CC